GB1468172A
(en)
*
|
1973-03-28 |
1977-03-23 |
Benzon As Alfred |
Oral drug preparations
|
DE2336218C3
(de)
*
|
1973-07-17 |
1985-11-14 |
Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz |
Orale Arzneiform
|
DE2343218C2
(de)
*
|
1973-08-28 |
1986-08-07 |
Hoechst Ag, 6230 Frankfurt |
Furosemid enthaltende Pellets
|
FR2377196A1
(fr)
*
|
1977-01-13 |
1978-08-11 |
Lipha |
Composition medicamenteuse a usage oral
|
GB1561204A
(en)
*
|
1977-06-01 |
1980-02-13 |
Ici Ltd |
Sustained release pharmaceutical composition
|
FR2397840B1
(fr)
*
|
1977-07-22 |
1981-03-20 |
Cherqui Jean |
|
US4153677A
(en)
*
|
1978-05-18 |
1979-05-08 |
Sterling Drug Inc. |
Controlled-release composition
|
GB1584130A
(en)
*
|
1978-05-30 |
1981-02-04 |
Wyeth John & Brother Ltd |
Indole derivatives
|
DD146547A5
(de)
*
|
1978-07-15 |
1981-02-18 |
Boehringer Sohn Ingelheim |
Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
|
SE426548B
(sv)
*
|
1978-12-05 |
1983-01-31 |
Haessle Ab |
Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
|
US4173626A
(en)
*
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
SE7813246L
(sv)
*
|
1978-12-22 |
1980-06-23 |
Haessle Ab |
Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
|
JPS55129219A
(en)
*
|
1979-03-29 |
1980-10-06 |
Asahi Chem Ind Co Ltd |
Slow-releasing preparation
|
US4252786A
(en)
*
|
1979-11-16 |
1981-02-24 |
E. R. Squibb & Sons, Inc. |
Controlled release tablet
|
US4543370A
(en)
*
|
1979-11-29 |
1985-09-24 |
Colorcon, Inc. |
Dry edible film coating composition, method and coating form
|
FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
DE3000979A1
(de)
*
|
1980-01-12 |
1981-07-23 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
|
DE3126703A1
(de)
|
1981-07-07 |
1983-01-27 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Bromhexin-retardform und verfahren zu ihrer herstellung
|
US4587118A
(en)
*
|
1981-07-15 |
1986-05-06 |
Key Pharmaceuticals, Inc. |
Dry sustained release theophylline oral formulation
|
WO1983000284A1
(fr)
*
|
1981-07-15 |
1983-02-03 |
Key Pharma |
Theophylline a liberation prolongee
|
US4508702A
(en)
*
|
1982-06-14 |
1985-04-02 |
Key Pharmaceuticals, Inc. |
Sustained release aspirin
|
EP0111560A4
(fr)
*
|
1982-06-14 |
1987-02-03 |
Key Pharma |
Aspirine a liberation entretenue.
|
US4415547A
(en)
*
|
1982-06-14 |
1983-11-15 |
Sterling Drug Inc. |
Sustained-release pharmaceutical tablet and process for preparation thereof
|
US4557925A
(en)
*
|
1982-07-08 |
1985-12-10 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
US4634587A
(en)
*
|
1982-07-09 |
1987-01-06 |
Key Pharmaceuticals, Inc. |
Sustained release quinidine dosage form
|
DE3382392D1
(de)
*
|
1982-07-09 |
1991-10-02 |
Key Pharma |
Dosierungsart zur dauerhaften verabreichung von chinidin.
|
IE55745B1
(en)
*
|
1983-04-06 |
1991-01-02 |
Elan Corp Plc |
Sustained absorption pharmaceutical composition
|
GB8322007D0
(en)
*
|
1983-08-16 |
1983-09-21 |
Wellcome Found |
Pharmaceutical delivery system
|
USRE33994E
(en)
*
|
1983-08-16 |
1992-07-14 |
Burroughs Wellcome Co. |
Pharmaceutical delivery system
|
JPS6051106A
(ja)
*
|
1983-08-31 |
1985-03-22 |
Yamanouchi Pharmaceut Co Ltd |
塩酸アモスラロ−ル持続性製剤
|
US4749575A
(en)
*
|
1983-10-03 |
1988-06-07 |
Bio-Dar Ltd. |
Microencapsulated medicament in sweet matrix
|
US4555399A
(en)
*
|
1983-11-18 |
1985-11-26 |
Key Pharmaceuticals, Inc. |
Aspirin tablet
|
DE3403329A1
(de)
*
|
1984-02-01 |
1985-08-01 |
Horst Dr. 4019 Monheim Zerbe |
Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
|
GB2159714B
(en)
*
|
1984-06-04 |
1988-05-05 |
Sterwin Ag |
Pharmaceutical composition of sparingly soluble medicament and method for its preparation
|
GB8414221D0
(en)
*
|
1984-06-04 |
1984-07-11 |
Sterwin Ag |
Unit dosage form
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
EP0467488B1
(fr)
*
|
1984-08-17 |
1995-10-11 |
The Wellcome Foundation Limited |
Composition à libération contrôlée d'une substance active
|
US4629620A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
US4629619A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
IE58110B1
(en)
*
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US4867984A
(en)
*
|
1984-11-06 |
1989-09-19 |
Nagin K. Patel |
Drug in bead form and process for preparing same
|
CA1268710A
(fr)
*
|
1984-11-06 |
1990-05-08 |
Nagin K. Patel |
Medicament sous forme de perles et procede de preparation
|
US4728512A
(en)
*
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US4666704A
(en)
*
|
1985-05-24 |
1987-05-19 |
International Minerals & Chemical Corp. |
Controlled release delivery system for macromolecules
|
US4904476A
(en)
*
|
1986-03-04 |
1990-02-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US4794001A
(en)
*
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US5286494A
(en)
*
|
1986-07-02 |
1994-02-15 |
Schering Aktiengesellschaft |
Medicinal agents with sustained action
|
JPS6327424A
(ja)
*
|
1986-07-17 |
1988-02-05 |
Shionogi & Co Ltd |
徐放性製剤およびその製造法
|
US4752470A
(en)
*
|
1986-11-24 |
1988-06-21 |
Mehta Atul M |
Controlled release indomethacin
|
US4786509A
(en)
*
|
1987-05-18 |
1988-11-22 |
Schering Corporation |
Dry sustained release theophylline oral formulation
|
US5122384A
(en)
*
|
1989-05-05 |
1992-06-16 |
Kv Pharmaceutical Company |
Oral once-per-day organic nitrate formulation which does not induce tolerance
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
US5084287A
(en)
*
|
1990-03-15 |
1992-01-28 |
Warner-Lambert Company |
Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
|
US5707652A
(en)
*
|
1990-12-04 |
1998-01-13 |
State Of Oregon |
Methods of treating circadian rhythm phase disorders
|
US6638963B1
(en)
|
1990-12-04 |
2003-10-28 |
Oregon Health And Science University |
Methods for treating circadian rhythm disorders
|
US5252337A
(en)
*
|
1991-06-25 |
1993-10-12 |
Eurand America, Inc. |
Controlled release calcium channel blocker microcapsules
|
IL110035A0
(en)
*
|
1994-06-16 |
1994-10-07 |
Tapuach Natural Technologies 1 |
Homeopathic formulations
|
US5834024A
(en)
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
FR2766367B1
(fr)
*
|
1997-07-22 |
2000-03-31 |
Plantes Et Medecines |
Granules homeopathiques et procede de fabrication
|
DE19732903A1
(de)
|
1997-07-30 |
1999-02-04 |
Falk Pharma Gmbh |
Pellet-Formulierung zur Behandlung des Intestinaltraktes
|
UA69413C2
(uk)
*
|
1998-05-22 |
2004-09-15 |
Брістол-Майерс Сквібб Компані |
Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
|
UA73092C2
(uk)
|
1998-07-17 |
2005-06-15 |
Брістол-Майерс Сквібб Компані |
Таблетка з ентеросолюбільним покриттям і спосіб її приготування
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US20050037086A1
(en)
*
|
1999-11-19 |
2005-02-17 |
Zycos Inc., A Delaware Corporation |
Continuous-flow method for preparing microparticles
|
US20040185099A1
(en)
*
|
2000-01-20 |
2004-09-23 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
US6254888B1
(en)
|
2000-01-28 |
2001-07-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for coating pharmaceutical dosage forms
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
AU2001268159B2
(en)
*
|
2000-06-02 |
2005-09-15 |
Eisai Inc. |
Delivery systems for bioactive agents
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
JP2004531467A
(ja)
|
2000-11-28 |
2004-10-14 |
エフ エム シー コーポレーション |
可食性pga被覆組成物
|
WO2003024430A1
(fr)
|
2001-09-21 |
2003-03-27 |
Egalet A/S |
Systeme a liberation de polymere de morphine
|
EP2957281A1
(fr)
*
|
2001-09-21 |
2015-12-23 |
Egalet Ltd. |
Systeme de liberation a base de polymere
|
AU2003225102A1
(en)
*
|
2002-04-23 |
2003-11-10 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
DE602004031096D1
(de)
|
2003-03-26 |
2011-03-03 |
Egalet As |
Morphin-system mit kontrollierter freisetzung
|
JP5161075B2
(ja)
*
|
2005-06-03 |
2013-03-13 |
エガレット エイ/エス |
分散媒体の第1フラクションとマトリックスの第2フラクションを有し、第2フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
|
EP2535044B1
(fr)
|
2006-01-27 |
2019-12-18 |
The Regents of The University of California |
Cysteamine bitartrate et cystamine a enrobage entérique
|
EP2104493A2
(fr)
*
|
2007-01-16 |
2009-09-30 |
Egalet A/S |
Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
|
CA2687192C
(fr)
|
2007-06-04 |
2015-11-24 |
Egalet A/S |
Compositions pharmaceutiques a liberation controlee pour un effet prolonge
|
CN104116736A
(zh)
|
2008-04-24 |
2014-10-29 |
百时美施贵宝公司 |
埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
|
EP2393484A1
(fr)
|
2009-02-06 |
2011-12-14 |
Egalet Ltd. |
Composition à libération immédiate résistant à une maltraitance par prise d'alcool
|
AU2010265213B2
(en)
|
2009-06-24 |
2012-08-23 |
Egalet Ltd. |
Controlled release formulations
|
WO2012100208A1
(fr)
|
2011-01-20 |
2012-07-26 |
Bionevia Pharmaceuticals Inc. |
Compositions à libération modifiée d'epalrestat ou d'un dérivé de celui-ci et leurs procédés d'utilisation
|
KR20140097132A
(ko)
|
2011-11-22 |
2014-08-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
허혈성 손상을 치료하기 위한 시스테아민 및/또는 시스타민
|
EP2861599B1
(fr)
|
2012-06-18 |
2019-12-18 |
Principia Biopharma Inc. |
Pyrrolo- ou pyrazolopyrimidines reversiblement covalents utiles pour le traitement du cancer ou de maladies auto-immunes
|
US20150140085A1
(en)
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
BR112015000150A2
(pt)
|
2012-07-06 |
2017-06-27 |
Egalet Ltd |
composições farmacêuticas dissuasoras de abuso de liberação controlada
|
TWI649100B
(zh)
|
2013-06-17 |
2019-02-01 |
地平線罕見醫學製藥有限責任公司 |
延遲釋放型半胱胺珠粒調配物,以及其製備及使用方法
|
WO2016105531A1
(fr)
|
2014-12-24 |
2016-06-30 |
Philip Nunn |
Dosage spécifique de site d'un inhibiteur de btk
|
RS62290B1
(sr)
|
2015-06-03 |
2021-09-30 |
Principia Biopharma Inc |
Inhibitori tirozinske kinaze
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
TWI759267B
(zh)
|
2015-07-02 |
2022-04-01 |
美商地平線罕見醫學製藥有限責任公司 |
Ado抗性半胱胺類似物及其用途
|
US10143665B2
(en)
|
2015-11-17 |
2018-12-04 |
Horizon Orphan Llc |
Methods for storing cysteamine formulations and related methods of treatment
|
MX2018006903A
(es)
*
|
2015-12-08 |
2018-11-09 |
Ardea Biosciences Inc |
Composicion farmaceutica.
|
JP7129704B2
(ja)
|
2016-06-29 |
2022-09-02 |
プリンシピア バイオファーマ インコーポレイテッド |
2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペント-2-エネニトリルの放出調節製剤
|
TW202140002A
(zh)
|
2020-01-20 |
2021-11-01 |
美商健臻公司 |
用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
|
CA3173330A1
(fr)
|
2020-04-17 |
2021-10-21 |
Genzyme Corporation |
Eclitasertib destine a etre utilise dans le traitement d'etats impliquant une reponse hyperinflammatoire systemique
|
EP4294427A1
(fr)
|
2021-02-19 |
2023-12-27 |
DuPont Nutrition Biosciences ApS |
Compositions pour la santé intestinale
|
CA3205786A1
(fr)
|
2021-02-23 |
2022-09-01 |
Otsuka Pharmaceutical Co., Ltd. |
Formulations pharmaceutiques de centanafadine et leurs procedes de fabrication et d'utilisation
|
WO2024006406A1
(fr)
|
2022-06-30 |
2024-01-04 |
Genzyme Corporation |
Inhibiteurs thérapeutiques de tyrosine kinase pour le traitement de la sclérose en plaques et de la myasthénie gravis
|
WO2024040043A1
(fr)
|
2022-08-16 |
2024-02-22 |
International N&H Denmark Aps |
Systèmes d'expression pour phosphatases
|
WO2024048782A1
(fr)
|
2022-09-02 |
2024-03-07 |
Otsuka Pharmaceutical Co., Ltd. |
1-(naphtalène-2-yl)-3-azabicyclo[3.1.0]hexane pour le traitement d'un trouble dépressif majeur
|
WO2024064653A1
(fr)
|
2022-09-20 |
2024-03-28 |
Dupont Nutrition Biosciences Aps |
Variants de polypeptides antiviraux
|